import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡å¯¦è­‰åœ–æ›¸é¤¨ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

# åˆå§‹åŒ– session_state ç”¨æ–¼è¯å‹•èˆ‡æŒä¹…åŒ–
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = "ğŸ“š RUBY (ENGOT-EN6)"

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === UI é«˜å°æ¯”åº¦èˆ‡è¦–è¦ºæ•‘æ´ === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F4F7F9; color: #1A1A1A;
        font-size: 19px !important; line-height: 1.1;
    }

    .main-title {
        font-size: 34px !important; font-weight: 900; color: #004D40;
        padding: 10px 0; border-bottom: 4px solid #4DB6AC; margin-bottom: 10px;
    }

    /* åœ–ä¸€ä¿®å¾©ï¼šå¤§éšæ®µ Header é£½å’Œæ¼¸å±¤èƒŒæ™¯ï¼Œç¢ºä¿ç™½è‰²æ–‡å­—æ¸…æ™° */
    .big-stage-card {
        border-radius: 12px; padding: 0px; box-shadow: 0 6px 25px rgba(0,0,0,0.15);
        border: 2.5px solid transparent; background: white; margin-bottom: 8px; overflow: hidden; height: auto !important;
    }
    .big-stage-header {
        font-size: 20px !important; font-weight: 900; color: white !important;
        padding: 14px; text-align: center; text-shadow: 1px 1px 3px rgba(0,0,0,0.5);
    }

    /* éšæ®µé…è‰²é£½å’ŒåŒ– */
    .card-p-tx { border-color: #1B5E20; }
    .header-p-tx { background: linear-gradient(135deg, #2E7D32, #1B5E20); } /* åˆæ²»: æ·±ç¶  */
    .card-p-mt { border-color: #0D47A1; }
    .header-p-mt { background: linear-gradient(135deg, #1565C0, #0D47A1); } /* ç¶­æŒ: æ·±è— */
    .card-r-tx { border-color: #BF360C; }
    .header-r-tx { background: linear-gradient(135deg, #E65100, #BF360C); } /* å¾©ç™¼: æ·±æ©˜ç´… */
    .card-r-mt { border-color: #4A148C; }
    .header-r-mt { background: linear-gradient(135deg, #6A1B9A, #4A148C); } /* å¾©å¾Œç¶­æŒ: æ·±ç´« */

    .sub-block {
        margin: 4px 8px; padding: 8px; border-radius: 10px; 
        background: #F8F9FA; border-left: 6px solid #455A64;
    }
    .sub-block-title {
        font-size: 16px; font-weight: 900; color: #263238;
        margin-bottom: 2px; border-bottom: 1.2px solid #CFD8DC; padding-bottom: 2px;
    }

    /* æŒ‰éˆ•æ¨£å¼ï¼šæ·±é»‘è‰²åŠ ç²— (#1A1A1A) */
    .stPopover button { 
        font-weight: 900 !important; font-size: 12px !important; 
        border-radius: 6px !important; margin-top: 3px !important;
        padding: 4px 10px !important; width: 100% !important; 
        text-align: left !important; color: #1A1A1A !important; 
        border: 1.5px solid rgba(0,0,0,0.2) !important;
        box-shadow: 0 2px 5px rgba(0,0,0,0.1) !important;
    }
    
    .stPopover button[aria-label*="ğŸ“š"] { background: #ECEFF1 !important; border-left: 6px solid #455A64 !important; }
    .stPopover button[aria-label*="ğŸ“"] { background: #E1F5FE !important; border-left: 6px solid #0288D1 !important; } 

    .detail-section { background: white; border-radius: 24px; padding: 35px; border: 1.5px solid #CFD8DC; box-shadow: 0 15px 50px rgba(0,0,0,0.1); }
    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 34px !important; font-weight: 900; color: #D84315; }
    .regimen-box { background: #F1F8E9; border-left: 6px solid #689F38; padding: 15px; border-radius: 8px; font-size: 15px; margin: 10px 0; line-height: 1.4; }
    .results-box { background: #FFF8E1; border: 1px solid #FFE082; padding: 10px; border-radius: 8px; margin-top: 5px; }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•æ•¸æ“šåº«ï¼šåˆ†å‹ã€éšæ®µèˆ‡è·¨çµ„å°èˆª ---
guidelines_nested = {
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "dMMR / MSI-H / MMRd", "content": "ä¸€ç·šé¦–é¸ï¼šå«é‰‘åŒ–ç™‚ + PD-1 (RUBY/GY018/AtTEnd)ã€‚"},
            {"title": "pMMR / NSMP / MSS", "content": "ä¸€ç·šç¶­æŒï¼šChemo + Durva/Ola (DUO-E)ã€‚äºŒç·šæ¨™é¶å…ç–« (KN775)ã€‚"},
            {"title": "POLE mutation (è¶…çªè®Šå‹)", "content": "é å¾Œæ¥µä½³ã€‚æ—©æœŸå¯è€ƒæ…®æ²»ç™‚é™éš (De-escalation)ã€‚"},
            {"title": "p53 mutation (é«˜æ‹·è²å‹)", "content": "ä¾µè¥²æ€§æœ€å¼·ã€‚å»ºè­°åŒ–æ”¾ç™‚ç©æ¥µä»‹å…¥ã€‚Serous å‹éœ€æª¢æ¸¬ HER2ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance Therapy", "content": "ä¸€ç·š IO æ²»ç™‚å¾Œå»¶çºŒç¶­æŒè‡³ PD (MK2870-033/DUO-E)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "Recurrent EC", "content": "æ¨™æº–äºŒç·šï¼šæ¨™é¶+å…ç–« (KN775) æˆ–å–®è—¥ IO (GARNET)ã€‚æ•‘æ´ ADC (SG)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "æ•‘æ´æ²»ç™‚å¾Œç¶­æŒç•¶å‰æœ‰æ•ˆæ–¹æ¡ˆç›´åˆ°ç–¾ç—…é€²å±•ã€‚"}]}
    ],
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "HGSC / Endometrioid", "content": "æ‰‹è¡“ (PDS/IDS) + Carbo/Pacli Â± Bevã€‚IDS åŠ  HIPEC (van Driel)ã€‚"},
            {"title": "Mucinous (MOC) é‘‘å®š", "content": "åˆ¤å®šï¼šCK7+/SATB2- (åŸç™¼)ã€‚IA æœŸå¯ä¿å®ˆã€‚ä¾µè¥²å‹å»ºè­°ç©æ¥µåŒ–ç™‚ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutation", "content": "Olaparib å–®è—¥ç¶­æŒ 2å¹´ (SOLO-1)ã€‚"}, 
            {"title": "HRD positive (wt)", "content": "PAOLA-1 (Ola+Bev) æˆ– PRIMA (Nira)ã€‚"},
            {"title": "HRD negative (pHRD)", "content": "Niraparib ç¶­æŒ (PRIMA ITT) æˆ– Bevacizumabã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "PSOC (Sensitive Recur)", "content": "PFI > 6mã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“ (DESKTOP III) æˆ–å«é‰‘è¤‡æ–¹ã€‚"},
            {"title": "PROC (Resistant Recur)", "content": "PFI < 6mã€‚å–®è—¥åŒ–ç™‚ Â± Bev æˆ–æ¨™é¶ ADC (MIRASOL)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "PARPi Maint", "content": "æ•‘æ´ç·©è§£å¾ŒçºŒç”¨ PARPi (NOVA/ARIEL3/SOLO2/DS8201)ã€‚"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "Locally Advanced (CCRT)", "content": "åŒæ­¥åŒ–æ”¾ç™‚ Â± åŒæ­¥ IO (A18) æˆ– èª˜å°åŒ–ç™‚ (INTERLACE)ã€‚"},
            {"title": "Early Stage (Surgery)", "content": "æ ¹æ²»è¡“ (LACC) æˆ–å–®ç´”åˆ‡é™¤ (SHAPE)ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance", "content": "1L æ–¹æ¡ˆå¾Œæ¥çºŒç¶­æŒ (KEYNOTE-826)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "Recurr / Metastatic", "content": "ä¸€ç·š KN826/BEATccã€‚äºŒç·š ADC (innovaTV 301) æˆ– IO (EMPOWER)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒç•¶å‰æœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³ PDã€‚"}]}
    ]
}

# --- 2. å¯¦è­‰è³‡æ–™åº« (33 é …è©¦é©—å…¨é‡æ•¸æ“šæ¥µé‡åŒ–è£œå®Œ) ---
all_trials_db = [
    # ==========================
    # === Endometrial Published ===
    # ==========================
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š RUBY (ENGOT-EN6/GOG-3031)", "pharma": "GSK", "drug": "Dostarlimab + Carboplatin/Paclitaxel", 
     "pop_results": "dMMR æ­»äº¡é¢¨éšªé™ä½ 68% (HR 0.32)",
     "rationale": "PD-1 é˜»æ–· (PD-1 blockade) èˆ‡å«é‰‘åŒ–ç™‚ (Carbo/Pacli) å…·å‚™å”åŒå…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ã€‚è—‰ç”±åŒ–ç™‚èª˜å°è…«ç˜¤æŠ—åŸé‡‹æ”¾ï¼Œé‡‹æ”¾å…ç–«å¾®ç’°å¢ƒå£“åŠ›ä¸¦é‡å° MMRd æ—ç¾¤é”æˆæ¥µé«˜æŒä¹…æ‡‰ç­”ç‡ã€‚",
     "regimen": "Arm 1 (Dostarlimab çµ„): èª˜å°æœŸ: Dostarlimab 500mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸï¼›ç¶­æŒæœŸ: Dostarlimab 1000mg Q6W (æŒçºŒ 3å¹´)ã€‚ Arm 2 (Placebo çµ„): ç”Ÿç†é¹½æ°´å°ç…§ + åŒåŠ‘é‡ CP åŒ–ç™‚ x6 é€±æœŸã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO Stage III-IV æˆ–é¦–æ¬¡å¾©ç™¼ä¹‹å­å®®å…§è†œç™Œ (EC)ã€‚", "ECOG 0-1ã€‚", "å« Carcinosarcoma / Clear cell / Serous ç­‰çµ„ç¹”å‹æ…‹ã€‚"],
     "exclusion": ["å…ˆå‰æ¥å—éå…¨èº«æ€§æŠ—ç™ŒåŒ–ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…ã€‚", "è‡¨åºŠé¡¯è‘—çš„é–“è³ªæ€§è‚ºç—…å²ã€‚"],
     "outcomes": "dMMR æ—ç¾¤ 24å€‹æœˆ PFS ç‡: 61.4% vs 15.7% (HR 0.28, 95% CI 0.16-0.50); ITT å…¨äººç¾¤ mOS HR 0.64 (95% CI 0.46-0.87, P=0.0021)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd", "pMMR / NSMP / MSS"], "name": "ğŸ“š NRG-GY018 (KEYNOTE-868)", "pharma": "MSD", "drug": "Pembrolizumab + Carboplatin/Paclitaxel", 
     "pop_results": "dMMR PFS HR 0.30; pMMR HR 0.54",
     "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) é‡å¡‘è…«ç˜¤å¾®ç’°å¢ƒï¼ŒPembrolizumab å¼·åŒ–ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„æŒä¹…æ€§ã€‚",
     "regimen": "Arm A: Pembrolizumab 200mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸ -> ç¶­æŒæœŸ: Pembrolizumab 400mg Q6W (æŒçºŒ 2å¹´)ã€‚ Arm B: Placebo + CP x6 é€±æœŸã€‚",
     "inclusion": ["Stage III/IV æˆ–å¾©ç™¼ ECã€‚", "æä¾› MMR æª¢æ¸¬ (IHC) å ±å‘Šã€‚", "ECOG 0-1ã€‚"],
     "outcomes": "dMMR PFS HR 0.30 (95% CI 0.19-0.48); pMMR PFS HR 0.54 (95% CI 0.41-0.71, P<0.001)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["pMMR / NSMP / MSS"], "name": "ğŸ“š DUO-E (ENGOT-EN9)", "pharma": "AZ", "drug": "Durvalumab + CP â†’ç¶­æŒ Â± Olaparib", 
     "results_short": "ä¸‰è—¥çµ„ pMMR PFS HR 0.57 (vs CP)",
     "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘ (PARPi) èˆ‡ PD-L1 æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µçš„å”åŒæ•ˆæœï¼ŒPARPi èª˜å°çš„ DNA æå‚·å¯å¢åŠ æ–°æŠ—åŸè² è·ï¼Œå¼·åŒ–å…ç–«æ‡‰ç­”ã€‚",
     "regimen": "Arm 1: CP åƒ…åŒ–ç™‚ (å°ç…§çµ„); Arm 2: CP+Durvalumab -> Durva 1500mg Q4W ç¶­æŒ; Arm 3: CP+Durvalumab -> Durva 1500mg Q4W + Olaparib 300mg bid ç¶­æŒç›´åˆ°ç–¾ç—…é€²å±•ã€‚",
     "outcomes": "pMMR Arm 3 (Ola+Durva) vs Arm 1: PFS HR 0.57 (95% CI 0.42-0.79); dMMR Arm 2 vs Arm 1: HR 0.42 (95% CI 0.22-0.80)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š AtTEnd (ENGOT-EN7)", "pharma": "Roche", "drug": "Atezolizumab + CP", 
     "results_short": "dMMR PFS HR 0.36; ITT OS HR 0.82",
     "rationale": "é©—è­‰ä¸€ç·š PD-L1 æŠ‘åˆ¶åŠ‘ä½µç”¨åŒ–ç™‚å°æ™šæœŸæˆ–å¾©ç™¼æ‚£è€…ä¹‹ç”Ÿå­˜å„ªå‹¢ã€‚",
     "regimen": "Arm A: Atezolizumab 1200mg Q3W + CP x6-8 é€±æœŸ -> ç¶­æŒ Atezolizumab 1200mg Q3Wã€‚ Arm B: Placebo + CP x6-8 é€±æœŸã€‚",
     "outcomes": "dMMR PFS: æœªé”åˆ° vs 6.9m (HR 0.36, 95% CI 0.23-0.57); å…¨äººç¾¤ mOS HR 0.82 (P=0.048)ã€‚"},
    
    {"cancer": "Endometrial", 
    "pos": "P-MT", 
    "sub_pos": ["Maintenance Therapy"], 
    "name": "ğŸ“š DUO-E (Maint)", 
    "pharma": "AstraZeneca", 
    "drug": "Durvalumab Â± Olaparib",
    "results_short": "pMMR PFS HR 0.57; ITT OS HR 0.77",
    "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘èˆ‡ PD-L1 æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µå° pMMR æ‚£è€…çš„å”åŒå¢æ•æ•ˆæ‡‰ã€‚",
    "regimen": "Arm 2: Durvalumab 1500mg Q4W ç¶­æŒ; Arm 3: Durvalumab + Olaparib 300mg bid ç¶­æŒã€‚",
    "inclusion": ["ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé” CR/PR ä¹‹æ™šæœŸ ECã€‚", "æä¾› MMR IHC ç‹€æ…‹ã€‚"],
    "exclusion": ["å…ˆå‰æ¥å—éç³»çµ±æ€§ IO æ²»ç™‚ã€‚"],
    "outcomes": "pMMR ä¸‰è—¥çµ„ (Ola+Durva) PFS HR 0.57 (95% CI 0.42-0.79)ã€‚"},
    
    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š KEYNOTE-775 (Study 309)", "pharma": "MSD/Eisai", "drug": "Lenvatinib + Pembrolizumab", 
     "results_short": "pMMR/MSS äºŒç·šæ¨™æº–ï¼šOS 17.4m vs 12.0m",
     "rationale": "çµåˆ VEGF-TKI é‡å¡‘è¡€ç®¡ä¸¦æ¸›è¼•å…ç–«æŠ‘åˆ¶ï¼Œå…‹æœ MSS è…«ç˜¤ä¹‹å…ç–«å†·å¾®ç’°å¢ƒã€‚",
     "regimen": "Lenvatinib 20mg QD (æ¯æ—¥å£æœ) + Pembrolizumab 200mg Q3W (éœè„ˆæ»´æ³¨) ç›´è‡³ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ã€‚",
     "inclusion": ["å…ˆå‰æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚é€²å±•ä¹‹æ™šæœŸ EC (æœ€å¤šå‰ç·š 2 æ¬¡)ã€‚", "ECOG 0-1ã€‚", "ä¸é™ MMR ç‹€æ…‹ã€‚"],
     "outcomes": "pMMR OS: 17.4m vs 12.0m (HR 0.68, 95% CI 0.56-0.84, P<0.001); ITT OS: 18.3m vs 11.4m (HR 0.62)ã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š GARNET", "pharma": "GSK", "drug": "Dostarlimab å–®è—¥", 
     "results_short": "dMMR ORR 45.5%; DOR æŒä¹…",
     "rationale": "é‡å° MSI-H/dMMR é«˜å…ç–«åŸæ€§æ‚£è€…ï¼Œå–®è—¥ PD-1 é˜»æ–·å³å¯é”æˆæŒä¹…æ‡‰ç­”ã€‚",
     "regimen": "Dostarlimab 500mg Q3W x4 åŠ‘ -> 1000mg Q6W ç¶­æŒç›´åˆ°é€²å±•ã€‚",
     "outcomes": "dMMR/MSI-H ORR 45.5%; DOR æœªé”åˆ°ã€‚"},

    # ==========================
    # === Cervical Published ===
    # ==========================
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š KEYNOTE-A18 (ENGOT-cx11)", "pharma": "MSD", "drug": "Pembrolizumab + CCRT", 
     "results_short": "LACC æ¨™æº–ï¼š36m OS 82.6% (HR 0.67)",
     "rationale": "å°‡å…ç–«æ•´åˆå…¥é«˜é¢¨éšªå±€éƒ¨æ™šæœŸä¹‹æ ¹æ²»åŒæ­¥åŒ–æ”¾ç™‚ã€‚",
     "regimen": "Arm A: CCRT (Cisplatin 40mg/m2 é€±æœ + RT 45-50.4 Gy) åŒæ­¥ Pembro 200mg Q3W x5 é€±æœŸ -> ç¶­æŒ Pembro 400mg Q6W x15 é€±æœŸã€‚ Arm B: CCRT + Placeboã€‚",
     "inclusion": ["æ–°è¨ºæ–· Stage IB2-IIB LN(+) æˆ– Stage III-IVA å±€éƒ¨æ™šæœŸã€‚"],
     "outcomes": "24m PFS: 68% vs 57% (HR 0.70); 36m OS: 82.6% vs 74.8% (HR 0.67)ã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š INTERLACE", "pharma": "UCL", "drug": "Induction Carbo/Pacli x6 -> CCRT", 
     "results_short": "5å¹´ OS 80% (vs 72%, HR 0.60)",
     "rationale": "åˆ©ç”¨èª˜å°åŒ–ç™‚ (Induction Chemo) è§£æ±ºæ”¾ç™‚å‰çš„å¾®å°è½‰ç§»ã€‚",
     "regimen": "èª˜å°æœŸ: Paclitaxel 80mg/m2 + Carboplatin AUC2 æ¯é€±ä¸€æ¬¡ x6 é€±æœŸ -> æ¥çºŒæ¨™æº– CCRT (Cisplatin + RT)ã€‚",
     "outcomes": "5yr OS: 80% vs 72% (HR 0.60); 5yr PFS: 73% vs 64% (HR 0.65)ã€‚"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š KEYNOTE-826", "pharma": "MSD", "drug": "Pembrolizumab + Chemo Â± Bev", 
     "results_short": "R/M ä¸€ç·šæ¨™æº–ï¼šOS HR 0.63",
     "rationale": "ä¸€ç·šè½‰ç§»æ€§å­å®®é ¸ç™Œå…ç–«çµ„åˆé»ƒé‡‘æ¨™æº–ã€‚",
     "regimen": "Arm 1: Pembrolizumab 200mg Q3W + Chemo (Pacli+Cis/Carbo) Â± Bevacizumab 15mg/kg Q3Wã€‚ Arm 2: Placebo + Chemo Â± Bevã€‚",
     "outcomes": "CPSâ‰¥1 mOS: 28.6m vs 16.5m (HR 0.60); å…¨äººç¾¤ OS HR 0.63ã€‚"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š innovaTV 301 (ENGOT-cx12)", "pharma": "Genmab", "drug": "Tisotumab Vedotin (ADC)", 
     "results_short": "å¾Œç·š ADC çªç ´ï¼šOS HR 0.70; ORR 17.8%",
     "rationale": "æ¨™é¶çµ„ç¹”å› å­ (Tissue Factor) ADCï¼Œè§£æ±ºå¾Œç·šåŒ–ç™‚è€è—¥ã€‚",
     "regimen": "Arm A: Tisotumab Vedotin 2.0 mg/kg IV Q3Wã€‚ Arm B: é†«å¸«é¸æ“‡åŒ–ç™‚ (Chemo SoC)ã€‚",
     "outcomes": "mOS: 11.5m vs 9.5m (HR 0.70); ORR 17.8% vs 5.2%ã€‚"},

    # ==========================
    # === Ovarian Published ===
    # ==========================
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)"], "name": "ğŸ“š MIRASOL (GOG-3045)", "pharma": "ImmunoGen", "drug": "Mirvetuximab Soravtansine", 
     "results_short": "PROC OS çªç ´ï¼šOS HR 0.67; ORR 42.3%",
     "rationale": "é‡å° FRÎ± é«˜è¡¨ç¾ PROC æ‚£è€…ï¼Œé¦–å€‹ ADC ç”Ÿå­˜ç²ç›Šç ”ç©¶ã€‚",
     "regimen": "Arm A: Mirvetuximab 6.0 mg/kg (AIBW) IV Q3W ç›´è‡³é€²å±•ã€‚ Arm B: é†«å¸«é¸æ“‡åŒ–ç™‚ (Pacli/PLD/Topo)ã€‚",
     "outcomes": "mOS: 16.4m vs 12.7m (HR 0.67); mPFS 5.6m vs 4.0m (HR 0.65)ã€‚"},

    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], "name": "ğŸ“š DESKTOP III", "pharma": "AGO", "drug": "Secondary Cytoreduction Surgery", 
     "results_short": "äºŒæ¬¡æ‰‹è¡“åƒ¹å€¼ï¼šR0 åˆ‡é™¤ mOS 53.7m",
     "rationale": "è­‰æ˜åš´é¸æ‚£è€… (AGO Score+) äºŒæ¬¡æ‰‹è¡“å…·ç”Ÿå­˜ç²ç›Šã€‚",
     "regimen": "æ‰‹è¡“çµ„: è…«ç˜¤å®Œå…¨åˆ‡é™¤æ‰‹è¡“å¾Œæ¥çºŒå«é‰‘åŒ–ç™‚ã€‚ åŒ–ç™‚çµ„: å–®ç´”å«é‰‘è¤‡æ–¹åŒ–ç™‚ã€‚",
     "inclusion": ["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PFI > 6m)ã€‚", "AGO Score é™½æ€§ (ECOG 0/å¤§é‡è…¹æ°´é™¤å¤–/R0 å®Œå…¨åˆ‡é™¤æ½›åŠ›)ã€‚"],
     "outcomes": "ITT mOS: 53.7m vs 46.0m (HR 0.75, 95% CI 0.59-0.96); R0 åˆ‡é™¤è€… mOS é” 61.9mã€‚"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š van Driel HIPEC", "pharma": "NEJM", "drug": "Surgery + HIPEC (Cisplatin)", 
     "results_short": "IDS åŠ æº«ï¼šmOS å»¶é•· 12 å€‹æœˆ (HR 0.67)",
     "rationale": "è¡“ä¸­åŠ æº«è…¹è…”åŒ–ç™‚å¼·åŒ–ç‰©ç†æ®ºå‚·èˆ‡æ»²é€åŠ›ã€‚",
     "regimen": "é–“æ­‡æ¸›ç©æ‰‹è¡“ (IDS) æ™‚åŒæ­¥é€²è¡ŒåŠ æº« (42Â°C) è…¹è…”çŒæ³¨ Cisplatin (100 mg/m2) 90 åˆ†é˜ã€‚",
     "outcomes": "mOS: 45.7m vs 33.9m (HR 0.67, 95% CI 0.48-0.94)ã€‚"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š LION", "pharma": "NEJM", "drug": "No Lymphadenectomy", 
     "results_short": "è‡¨åºŠ LN é™°æ€§å…æ¸…æƒï¼šOS ç„¡å·®ç•° (HR 1.06)",
     "outcomes": "mOS: 65.5m vs 69.2m (HR 1.06)ã€‚è‡¨åºŠ LN(-) è€…å…æ¸…æƒã€‚"},
    
    {"cancer": "Ovarian", 
    "pos": "P-MT", 
    "sub_pos": ["HRD positive (wt)", "HRD negative (pHRD)"], 
    "name": "ğŸ“š DUO-O (ENGOT-OV46)", 
    "pharma": "AstraZeneca", 
    "drug": "Durvalumab + Olaparib + Bev",
    "results_short": "HRD+ ä¸‰è—¥çµ„ PFS HR 0.49; ITT HR 0.63",
    "rationale": "åˆ©ç”¨ IO + PARPi + anti-VEGF ä¸‰è—¥è¯ç”¨ï¼Œæ–¼ä¸€ç·šåæ‡‰å¾Œæ¸…é™¤å¾®å°æ®˜ç•™ç—…ç¶ä¸¦å»¶ç·©å¾©ç™¼ã€‚",
    "regimen": "Arm 3: Bevacizumab + Durvalumab + Olaparib (300mg bid) ç¶­æŒç›´è‡³ç–¾ç—…é€²å±•ã€‚",
    "inclusion": ["æ–°è¨ºæ–· FIGO III-IV æœŸä¸Šçš®æ€§åµå·¢ç™Œã€‚", "æ¥å— PDS æˆ– IDS ä¸”å°é‰‘é¡æœ‰åæ‡‰ã€‚"],
    "exclusion": ["éä¸Šçš®æ€§åµå·¢ç™Œã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚"],
    "outcomes": "HRD+ (non-BRCAm) PFS HR 0.49 (95% CI 0.34-0.69); ITT ITT HR 0.63ã€‚"},
    
    {"cancer": "Ovarian", "pos": "PR-Maint", "sub_pos": ["PARPi Maint"], "name": "ğŸ“š SOLO2", "pharma": "AZ", "drug": "Olaparib å¾©ç™¼ç¶­æŒ", 
     "results_short": "BRCAm é•·æœŸ mOS 51.7m (HR 0.74)",
     "outcomes": "mOS: 51.7m vs 38.8m (HR 0.74)ã€‚"},

    # ==========================
    # === Ongoing Trials (8æ ¸å¿ƒæ¥µé‡åŒ–) ===
    # ==========================
    {"cancer": "Endometrial", "name": "ğŸ“ MK2870-033", "pharma": "MSD", "drug": "Sac-TMT + Pembrolizumab", "pos": "P-MT", "sub_pos": ["Maintenance Therapy"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Trop-2 ADC (Sac-TMT) å”åŒ PD-1ã€‚é€é ADC èª˜å°ä¹‹ ICD æ”¹å–„å¾®ç’°å¢ƒï¼Œæ—¨åœ¨æå‡ pMMR æˆ– NSMP æ‚£è€…ä¸€ç·šç¶­æŒéšæ®µæ‡‰ç­”æ·±åº¦èˆ‡æŒçºŒæ™‚é–“ã€‚",
     "regimen": "Arm A (åˆ†çµ„ 1): Sac-TMT 5mg/kg Q6W + Pembrolizumab 400mg Q6W ç¶­æŒæ²»ç™‚ç›´åˆ° PDã€‚ Arm B (åˆ†çµ„ 2): é†«å¸«é¸æ“‡ç¶­æŒæ–¹æ¡ˆ (å°ç…§çµ„)ã€‚",
     "inclusion": ["æ–°è¨ºæ–· pMMR/MSS å­å®®å…§è†œç™Œ (ä¸­å¿ƒ IHC æª¢æ¸¬ç¢ºèª)ã€‚", "FIGO III-IV æœŸã€ä¸€ç·šå«é‰‘åŒ–ç™‚ + Pembrolizumab å¾Œé” CR/PRã€‚"],
     "exclusion": ["å…ˆå‰æ¥å—éé‡å°å¾©ç™¼ç—…ç¶ä¹‹ç³»çµ± IO æ²»ç™‚ã€‚", "çµ„ç¹”å­¸ç‚ºå­å®®è‚‰ç˜¤ (Sarcoma)ã€‚"]},

    {"cancer": "Ovarian", "name": "ğŸ“ FRAmework-01 (LY4170156)", "pharma": "Eli Lilly", "drug": "LY4170156 + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)", "PSOC (Sensitive Recur)"], "type": "Ongoing",
     "rationale": "æ¨™é¶ FRÎ± ADC è¯ç”¨ anti-VEGFã€‚åˆ©ç”¨ Bevacizumab è¡€ç®¡èª¿ç¯€ä½œç”¨é™ä½è…«ç˜¤é–“è³ªå£“ï¼Œæå‡ ADC æ–¼å¯¦é«”è…«ç˜¤å…§çš„æ»²é€æ·±åº¦æŒ‘æˆ°è€è—¥ç“¶é ¸ã€‚",
     "regimen": "PROC éšŠåˆ—åˆ†çµ„ï¼š Arm A: LY 3.0mg/kg + Bev 15mg/kg Q3W; Arm B: LY 4.0mg/kg + Bev 15mg/kg Q3Wã€‚ PSOC éšŠåˆ— (PFI 6-12m): Arm C: LY 3.0mg/kg + Bev 15mg/kg Q3Wã€‚ å°ç…§çµ„ (Arm D): é†«å¸«é¸æ“‡åŒ–ç™‚ SoCã€‚",
     "inclusion": ["ç¶“æª¢æ¸¬ç¢ºèª FRÎ± è¡¨é”é™½æ€§ (IHC)ã€‚", "æœ€å¾Œé‰‘é¡å¾Œé€²å±•ä¹‹ PROC æˆ– PSOC (PFI 90d-365d)ã€‚"],
     "exclusion": ["æ›¾ç”¨éé‡å° FRÎ± ä¹‹ ADC (å¦‚ Enhertu æ›¾è©¦éè€…éœ€è©•ä¼°)ã€‚", "æ´»å‹•æ€§é–“è³ªæ€§è‚ºç—… (ILD)ã€‚"]},

    {"cancer": "Endometrial", "name": "ğŸ“ GU-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "type": "Ongoing",
     "rationale": "é‡å° Trop-2 æ¨™é¶ã€‚åˆ©ç”¨ SN-38 è¼‰è·å¼•ç™¼å¼·åŠ› DNA æå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) å¤±æ•—å¾Œä¹‹å¾©ç™¼æ•‘æ´ã€‚",
     "regimen": "Sacituzumab govitecan 10mg/kg (Day 1, Day 8) æ¯ 21 å¤©ç‚ºä¸€é€±æœŸ (Q21D) ç›´è‡³ç–¾ç—…é€²å±•ã€‚",
     "inclusion": ["å¾©ç™¼æ€§ EC (ä¸å«è‚‰ç˜¤)ã€‚", "å…ˆå‰æ›¾æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚åŠ PD-1/L1 å¤±æ•—é€²å±•è€…ã€‚", "ECOG 0-1ã€‚"]},

    {"cancer": "Ovarian", "name": "ğŸ“ DOVE", "pharma": "GSK", "drug": "Dostarlimab + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)"], "type": "Ongoing",
     "rationale": "é‡å° OCCC é€æ˜ç´°èƒç™Œã€‚åˆ©ç”¨ PD-1 + anti-VEGF é›™é‡é˜»æ–·æ”¹å–„å…¶ç‰¹æœ‰ä¸”é«˜åº¦å…ç–«æŠ‘åˆ¶ä¹‹å¾®ç’°å¢ƒã€‚",
     "regimen": "Dostarlimab 1000mg Q6W + Bevacizumab 15mg/kg Q3W ç›´è‡³é€²å±•ã€‚"},

    {"cancer": "Ovarian", "name": "ğŸ“ DS8201-772 (Enhertu)", "pharma": "AstraZeneca", "drug": "T-DXd", "pos": "P-MT", "sub_pos": ["BRCA mutation", "HRD positive (wt)"], "type": "Ongoing",
     "rationale": "æ¨™é¶ HER2 ADC ç”¨æ–¼ç¶­æŒã€‚åˆ©ç”¨ T-DXd æ¥µé«˜ DAR (8) å„ªå‹¢æ¸…é™¤åŒ–ç™‚å¾Œæ®˜é¤˜ä¹‹ HER2 è¡¨ç¾å¾®å°ç—…ç¶ã€‚",
     "regimen": "Trastuzumab deruxtecan 5.4mg/kg IV Q3W ç¶­æŒè‡³é€²å±•ã€‚"},
]

# --- 3. AI æ¨¡å‹å·¡é‚èˆ‡è¯å‹•åŠŸèƒ½ ---
def get_gemini_model():
    try:
        available_models = [m.name for m in genai.list_models() if 'generateContent' in m.supported_generation_methods]
        target_model = next((m for m in available_models if 'gemini-1.5-flash' in m), None)
        if not target_model: target_model = next((m for m in available_models if 'gemini-pro' in m), None)
        if target_model: return genai.GenerativeModel(target_model)
    except: return None

# --- 4. å´é‚Šæ¬„ï¼šæ±ºç­–åŠ©ç† ---
with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI å¯¦è­‰åª’åˆåŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ æ‚£è€…ç—…æ­·æ•¸æ“šæ·±åº¦åˆ†æ", expanded=True):
        p_notes = st.text_area("è¼¸å…¥æ‘˜è¦ (å«åˆ†æœŸ/ç´°èƒ/æ¨™è¨˜)", placeholder="ä¾‹å¦‚ï¼šEC Stage III, dMMR, p53 mutation, HER2 2+...", height=250)
        if st.button("ğŸš€ é–‹å§‹åª’åˆåˆ†æ"):
            if api_key and p_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = get_gemini_model()
                    prompt = f"åˆ†æç—…æ­·ï¼š{p_notes}ã€‚è«‹åƒè€ƒå¯¦è­‰åº«ï¼š{all_trials_db}ã€‚å»ºè­°é©åˆè·¯å¾‘èˆ‡è©¦é©—ç†ç”±ã€‚"
                    st.write(model.generate_content(prompt).text)
                except Exception as e: st.error(f"AI ç•°å¸¸: {e}")

# --- 5. ä¸»é é¢ï¼šå°èˆªåœ°åœ–ä½ˆå±€ ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠå°èˆªå„€è¡¨æ¿ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Endometrial", "Ovarian", "Cervical"], horizontal=True)

cols = st.columns(len(guidelines_nested[cancer_type]))
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            
            # åˆä½µå¯¦è­‰æ¸²æŸ“æŒ‰éˆ•
            rel_trials = [t for t in (all_trials_db) if t["cancer"] == cancer_type and t["pos"] == stage["id"] and any(s in sub["title"] for s in t["sub_pos"])]
            for t in rel_trials:
                label = f"{t.get('pharma', 'N/A')} | {t['name']} | {t['drug']}"
                with st.popover(label, use_container_width=True):
                    # å±•ç¤ºç°¡å–®ç™‚æ•ˆå°çµè«– (åœ–ä¸‰ä¿®å¾©)
                    st.success(f"**æ ¸å¿ƒçµè«–æ‘˜è¦:** {t.get('pop_results', 'æ‹›å‹Ÿä¸­/è©³è¦‹æ·±åº¦çœ‹æ¿')}")
                    # åŒæ­¥è¯å‹•é‚è¼¯ï¼šé»æ“Šè§¸ç™¼ rerun åŒæ­¥çœ‹æ¿
                    unique_key = f"sync_{t['name']}_{cancer_type}_{stage['id']}_{sub['title'].replace(' ', '')}"
                    if st.button("ğŸ“Š åŒæ­¥çœ‹æ¿ç´°ç¯€", key=unique_key):
                        st.session_state.selected_trial = t['name']
                        st.rerun() 
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 6. æ·±åº¦æ•¸æ“šçœ‹æ¿ (æ¥µé‡åŒ–è³‡è¨Šå±•ç¤ºå€) ---
st.divider()
st.subheader("ğŸ“‹ è‡¨åºŠç ”ç©¶æ¥µé‡åŒ–æ•¸æ“šåº« (Published Milestones & Ongoing Trials)")
filtered_names = [t["name"] for t in all_trials_db if t["cancer"] == cancer_type]

if not filtered_names:
    st.info("è©²ç™Œç—‡é¡åˆ¥ä¸‹ç›®å‰ç„¡é©ç”¨å¯¦è­‰æˆ–è¨ˆç•«ã€‚")
else:
    try: curr_idx = filtered_names.index(st.session_state.selected_trial)
    except: curr_idx = 0

    selected_name = st.selectbox("ğŸ¯ å¿«é€Ÿé¸æ“‡ç ”ç©¶è¨ˆç•«ä»¥æŸ¥é–±åˆ†çµ„èˆ‡æ•¸æ“šï¼š", filtered_names, index=curr_idx, key="trial_selector")
    st.session_state.selected_trial = selected_name
    t_obj = next(it for it in all_trials_db if it["name"] == selected_name)

    st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
    st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:10px; font-weight:900;'>ğŸ“‹ {t_obj['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

    r1, r2 = st.columns([1.3, 1])
    with r1:
        st.markdown("<div style='background:#E3F2FD; border-left:10px solid #1976D2; padding:15px; border-radius:10px;'><b>ğŸ’‰ Rationale & Regimen (æ©Ÿè½‰èˆ‡åˆ†çµ„çµ¦è—¥)</b></div>", unsafe_allow_html=True)
        st.write(f"**è—¥å» :** {t_obj.get('pharma', 'N/A')} | **æ ¸å¿ƒé…æ–¹:** {t_obj['drug']}")
        
        # æ¥µé‡åŒ–çµ¦è—¥æ–¹æ¡ˆ (Dosing Protocol) - è£œé½Šåˆ†çµ„ç´°ç¯€
        st.markdown("<div class='regimen-box'><b>åˆ†çµ„çµ¦è—¥æ–¹å¼ (Regimen per Arm):</b><br>" + t_obj.get('regimen', 'æ­£åœ¨è£œé½Šåˆ†çµ„çµ¦è—¥ç´°ç¯€ã€‚') + "</div>", unsafe_allow_html=True)
        
        st.success(f"**ç§‘å­¸ç†æ“š (Scientific Rationale):** {t_obj.get('rationale', 'æ—¨åœ¨æŒ‘æˆ° SoC ç“¶é ¸æå‡ç²ç›Šã€‚')}")

    with r2:
        st.markdown("<div style='background:#FFF8E1; border-left:8px solid #FBC02D; padding:15px; border-radius:10px;'><b>ğŸ“ˆ Key Outcomes (æœ€æ–°ç”Ÿå­˜èˆ‡ç·©è§£æŒ‡æ¨™)</b></div>", unsafe_allow_html=True)
        st.markdown(f"""
            <div style='text-align:center; background:white; padding:15px; border:2px solid #FFE082; border-radius:12px;'>
                <div style='font-size: 14px; color: #795548; font-weight:700; margin-bottom:5px;'>Survival Metrics (PFS/OS/HR/ORR)</div>
                <div class='hr-big-val'>{t_obj.get('outcomes', t_obj.get('results_short', 'Ongoing Recruitment'))}</div>
            </div>
        """, unsafe_allow_html=True)
        

    st.divider()
    r3, r4 = st.columns(2)
    with r3:
        st.markdown("<div style='background:#E8F5E9; border-left:8px solid #2E7D32; padding:15px; border-radius:10px;'><b>âœ… Inclusion Criteria (é—œéµç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t_obj.get('inclusion', ['ç¬¦åˆåˆ†å­æ¨™è¨˜åˆ†å‹èˆ‡å‰ç·šè¦å®šã€‚']): st.write(f"â€¢ **{inc}**")
    with r4:
        st.markdown("<div style='background:#FFEBEE; border-left:8px solid #C62828; padding:15px; border-radius:10px;'><b>âŒ Exclusion Criteria (é—œéµæ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t_obj.get('exclusion', ['æ’é™¤è‡Ÿå™¨åŠŸèƒ½ç•°å¸¸æˆ–æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…ã€‚']): st.write(f"â€¢ **{exc}**")
    st.markdown("</div>", unsafe_allow_html=True)
